AMCP Legislative & Regulatory Briefing — February 2025

AMCP Statement on Potential Staff Cuts to Department of Health and Human Services
Last week, officials within the Department of Health and Human Services (HHS) were tasked with identifying and ranking thousands of probationary employees, stoking fears of mass layoffs throughout the federal government. 

AMCP Publishes Policy Brief on Budget Reconciliation
This month, AMCP published a Policy Brief on the congressional budget reconciliation process and its impact on health policy in 2025.

AMCP Statement on President Trump’s New Tariffs
On Feb. 1, President Trump declared his intent to implement 25% additional tariffs on all imports from Canada and Mexico, as well as a 10% additional tariff on imports fromChina.

AMCP Comments on CMS Proposed Rules for CY 2026
Last November, the Biden administration released a proposed rule on technical changes to the Medicare Advantage and Part D programs for Contract Year (CY) 2026.

AMCP Provides Comments to the Expedited Program for Serious Conditions – Accelerated Approval of Drugs and Biologics
Last month, the Food and Drug Administration (FDA) unveiled draft guidance on the Expedited Program for Serious Conditions – Accelerated Approval of Drugs and Biologics.

AMCP Holds 2025 Policy Outlook Webinar
Last month, AMCP’s Adam Colborn, Associate Vice President of Government Affairs, and Geni Tunstall, Associate Vice President of Regulatory Affairs, presented an hour-long webinar titled Policy Outlook 2025: The Trump Administration and the 119th Congress.

AMCP Comments on Draft CY 2026 Part D Redesign Program Instructions
On Jan. 10, the Biden administration released the Draft CY 2026 Part D Redesign Program Instructions, which offers draft guidance on implementing changes to the Medicare Part D benefit as mandated by the Inflation Reduction Act.

Download Full Briefing